Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?
about
MAO-inhibitors in Parkinson's DiseaseAvailable and emerging treatments for Parkinson's disease: a reviewNovel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson's diseaseNonpharmacological treatments for patients with Parkinson's disease.Clinician versus machine: reliability and responsiveness of motor endpoints in Parkinson's diseaseSeniors with Parkinson's disease: initial medical treatment.Olfaction as a biomarker in Parkinson's disease.Parkinson's disease--the continuing search for biomarkers.Defining meaningful outcome measures in trials of disease-modifying therapies in Parkinson's disease.Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson's disease.Explaining ADAGIO: a critical review of the biological basis for the clinical effects of rasagiline.Pharmacological treatment and the prospect of pharmacogenetics in Parkinson's disease.Cheaper, simpler, and better: tips for treating seniors with Parkinson disease.Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease.Urate in Parkinson's disease: more than a biomarker?Initial treatment of Parkinson's disease: an update.Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms.Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson's disease.Experimental trials in amyotrophic lateral sclerosis: a review of recently completed, ongoing and planned trials using existing and novel drugs.Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson's disease.Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression.Algorithms for the treatment of motor problems in Parkinson's disease.Disease modification in Parkinson's disease.Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders.App-Based Bradykinesia Tasks for Clinic and Home Assessment in Parkinson's Disease: Reliability and Responsiveness.No synergism between bis(propyl)-cognitin and rasagiline on protecting dopaminergic neurons in Parkinson's disease mice.
P2860
Q24629770-0150B74D-9B91-49A7-967F-B05402C4E5D2Q24633444-EC43F0C5-C578-481D-A2DB-42994879D6CCQ27301283-D9472D96-21DC-4021-97A4-BD11DD9DC7FBQ30377906-62D4D4FA-DAF0-4217-BE0D-D2FDB4E77481Q33639008-0F94CAAE-0ED2-418F-B7E5-E448538D6154Q34508143-3138436F-C90F-481A-B79D-AA9557ADC44AQ37800097-BFEAB645-854B-4D0F-91FE-7487A7E49716Q37834648-B98B6896-AE5D-4FA7-950E-BDE5EBCB5B5CQ37846235-39ABA93B-ABA2-4500-9667-0B6CD2C2B940Q37855572-E82F511F-2E47-4252-B179-4E1ADA95A20EQ37939755-E5E09C04-B943-49A0-8A12-D931E21B6657Q37957393-C8E3C79E-8142-40C7-AB8F-CAF032591D77Q37963796-FFBB85B5-6FEE-49BD-8ED3-C2EFB0335715Q37996077-BDFA71EC-FA8D-4C44-9413-1C8CBD8F88F8Q38009670-A3B915BA-52F1-409E-A393-8E2569A48320Q38104296-D48B0162-D403-4AD5-8457-3012984B6A56Q38112214-A8A33116-4719-40A1-A587-FAD321E8D9A8Q38134903-697649E7-978A-4CD7-9199-58288E80BBE7Q38223292-1292B519-434C-448F-B38E-5BD306F11F4FQ38246682-3562D9FD-C139-4F45-A520-5FAFB815268EQ38325601-CC724A37-4770-43C7-9BE8-80C0D9ED2389Q38992788-5977C83B-ED82-4EB1-8A34-4FCC9D1F87E4Q44713421-B555341B-58EA-4564-8692-577A239F0BE9Q47593688-BEFE8480-53BE-4E12-B22C-E1C51D57EF77Q48108026-2D24B338-275C-4CDF-B66E-78A364F420FCQ48343609-A9644A12-8D78-4D6B-B804-64C35B2F41CC
P2860
Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?
@en
Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?
@nl
type
label
Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?
@en
Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?
@nl
prefLabel
Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?
@en
Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?
@nl
P2860
P1433
P1476
Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?
@en
P2860
P304
P356
10.1212/WNL.0B013E3181D7D8E2
P407
P577
2010-04-01T00:00:00Z